When a Buyer Retrades After LOI: How Founders Should Respond

You have an LOI. The headline number looked right, the buyer seemed credible, and exclusivity is running. Then, six weeks into diligence, the buyer's banker calls your advisor with a revised indication — price is down $800K, they've identified some working capital issues, and they're flagging a customer concentration concern they want reflected in an earnout. This moment — the retrade — is one of the most common and least-discussed events in lower middle market M&A.

The retrade creates asymmetric pressure. The seller has spent 6–8 weeks in diligence, management time has been consumed, employees may have been informed, and the seller is psychologically invested in closing. The buyer knows this. Some retrades are legitimate — diligence genuinely surfaces something that changes value. Many are not. The founder who cannot distinguish the two, and who has no framework for responding, gives up significant proceeds.

This guide covers why buyers retrade, how to evaluate each retrade claim, a practical negotiating framework, when to walk, and how preparation before the process reduces your exposure.

Why buyers retrade: four categories

Not all retrades are created equal. The buyer's stated reason is often different from the actual reason. Understanding the four underlying categories helps you calibrate your response.

Quality of Earnings (QoE) adjustments are the most common legitimate basis for a retrade. A buyer's QoE firm reviews normalized EBITDA and finds items the seller included that should not be — a personal expense run through the business, a one-time vendor credit that inflated margins, or a revenue recognition issue. If the QoE adjustment is real and verifiable, the price reduction is proportional: if the business was valued at 6x EBITDA and QoE reduces EBITDA by $150K, the buyer has a legitimate $900K reduction claim.

Working capital disputes are a frequent source of retrades that founders often do not anticipate. The LOI sets a working capital target but may not precisely define what is included. At closing, the buyer's definition of normalized working capital may differ from the seller's, creating a closing adjustment that functions as an effective price reduction. This is partly mechanical (accounting methodology) and partly negotiated.

Opportunistic retrades — where no new information justifies the adjustment — are more common than buyers admit. These often happen when: the buyer's financing came in at a lower amount than expected; the buyer's investment committee is pushing back on price; the fund is under pressure; or the buyer simply believes the seller is too far along to walk. Recognizing opportunistic retrades requires experience reading buyer behavior.

How to evaluate each retrade claim

Your first task when a retrade arrives is analysis, not reaction. Every retrade claim should be evaluated on three dimensions: Is it based on verified new information? Is the quantum proportionate to the finding? Is the finding something a prepared seller should have disclosed preemptively?

For QoE-driven retrades, compare the finding to your own financial records. If a buyer's QoE firm is adjusting out $120K of EBITDA for what they're calling a non-recurring vendor credit, pull the vendor history — if credits of that magnitude recur every 18 months, the adjustment is overstated. The quantum of a QoE adjustment is often negotiable even when the basis is legitimate.

For working capital retrades, review the LOI's working capital definition language. Many LOIs use vague language like "normalized working capital consistent with historical levels." That ambiguity is the buyer's entry point. Reconstruct the trailing twelve-month working capital calculation under both the buyer's and your methodology and understand the gap before any negotiation conversation.

The negotiating framework: what to give vs. fight

Not every retrade should be fought. The founder who refuses to acknowledge any legitimate finding loses credibility and may lose the deal over an amount smaller than the cost of a re-run process. The founder who accepts every retrade claim without evaluation gives up real money.

The framework: concede what is demonstrably true, negotiate the quantum of things that are real but sized aggressively, and reject what is not supported by evidence. Communicate each position in writing, clearly, with your own analysis attached.

Dollar math example: A buyer retrades on a $22M deal (6x on $3.67M EBITDA) with three claims. Claim 1: $100K QoE adjustment (owner salary normalization was overstated) — legitimate, verified. Concede $600K price reduction. Claim 2: $80K working capital shortfall — partially legitimate (methodology difference accounts for $35K; the remaining $45K is real). Concede $270K, counter on the $210K methodology portion. Claim 3: $150K EBITDA adjustment for "customer concentration risk" — not a QoE item, not a new finding, and was disclosed in the CIM. Reject entirely.

Structure alternatives can bridge gaps without pure price reductions. If a buyer is concerned about a specific risk (key customer, pending litigation, regulatory uncertainty), propose addressing it through deal structure rather than price: an escrow holdback against the specific item, an earnout tied to the specific risk event, or a representation and warranty insurance policy that covers the disputed item.

Earnouts and escrow as retrade responses

When a buyer retrades on the basis of uncertainty — rather than a verified error — structure is often a better response than a price concession. Earnouts and escrows allow the seller to say: "We disagree on the risk, so let's structure the payment to reflect resolution of that risk rather than pricing it in at close."

The risk of accepting an earnout in response to a retrade is that you are accepting a deferred payment for proceeds you believed were certain at LOI. Earnouts in lower middle market deals have notoriously low achievement rates — GF Data research suggests fewer than 60% of earnout recipients collect the full earnout amount. If you accept an earnout to bridge a retrade gap, the economic terms of the earnout (metric, measurement period, payment triggers) are critical.

Rollover equity is a common retrade response in PE transactions. The buyer asks for a larger rollover from the seller — effectively reducing cash at close — in exchange for maintaining headline price. From the buyer's perspective, it reduces their equity check and aligns the seller. From the seller's perspective, it converts guaranteed proceeds into illiquid equity in a company you no longer control. Evaluate the rollover request against the quality of the PE firm's track record and the specifics of the value creation plan.

When to walk: the credible exit threat

The seller's most powerful late-stage leverage is a credible willingness to walk from the deal. This requires two things: (1) you actually are willing to walk, and (2) the buyer believes you. Neither is automatic in practice.

Founders who are emotionally or financially dependent on the current deal closing are unable to credibly threaten to walk. Buyers are often skilled at reading this. The antidote is process design: running a competitive process with 3–5 qualified buyers means you have alternatives. A retrade in a competitive process carries a different risk profile for the buyer — if they push too hard, you go back to the second bidder.

The decision to walk should be made based on: (1) the magnitude of the retrade relative to your reservation price, (2) the credibility of your alternatives, (3) the stage of diligence (earlier is easier to re-start), and (4) the time remaining in your preferred transaction window. A retrade that takes a $22M deal to $19.5M when your reservation price was $20M is a walk. A retrade that takes a $22M deal to $21.2M on verified findings is probably not.

How preparation reduces retrading risk

The best defense against retrading is a prepared seller. Buyers retrade most aggressively when they find things in diligence that the seller did not disclose or did not know. Surprises — not unfavorable facts — are what drive the largest retrades.

A pre-deal Quality of Earnings analysis, conducted by an accounting firm before you run a process, eliminates the largest category of retrade risk. When you already have a QoE that normalizes EBITDA the way a buyer's QoE firm would, there is nothing for the buyer's QoE to find. The CIM and data room can be built around the QoE conclusions, and any issues the QoE surfaces can be resolved or disclosed before the process.

The math on preparation investment vs. retrade risk: a pre-deal QoE costs $25K–$60K for a $10M–$50M company. A retrade on an undisclosed QoE item typically costs $300K–$1.5M in price reduction. The ROI on preparation is not close.

FAQ: Buyer retrading after LOI